Ryan M Van Wagoner1, Amy Eichner2, Shalender Bhasin3, Patricia A Deuster4, Daniel Eichner1. 1. Sports Medicine Research and Testing Laboratory, Salt Lake City, Utah. 2. US Anti-Doping Agency, Colorado Springs, Colorado. 3. Research Program in Men's Health: Aging and Metabolism, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts. 4. Consortium for Health and Military Performance, Uniformed Services University, Bethesda, Maryland.
Abstract
Importance: Recent reports have described the increasing use of nonsteroidal selective androgen receptor modulators, which have not been approved by the US Food and Drug Administration (FDA), to enhance appearance and performance. The composition and purity of such products is not known. Objective: To determine the chemical identity and the amounts of ingredients in dietary supplements and products marketed and sold through the internet as selective androgen receptor modulators and compare the analyzed contents with product labels. Design and Setting: Web-based searches were performed from February 18, 2016, to March 25, 2016, using the Google search engine on the Chrome and Internet Explorer web browsers to identify suppliers selling selective androgen receptor modulators. The products were purchased and the identities of the compounds and their amounts were determined from April to August 2016 using chain-of-custody and World Anti-Doping Association-approved analytical procedures. Analytical findings were compared against the label information. Exposures: Products marketed and sold as selective androgen receptor modulators. Main Outcomes and Measures: Chemical identities and the amount of ingredients in each product marketed and sold as selective androgen receptor modulators. Results: Among 44 products marketed and sold as selective androgen receptor modulators, only 23 (52%) contained 1 or more selective androgen receptor modulators (Ostarine, LGD-4033, or Andarine). An additional 17 products (39%) contained another unapproved drug, including the growth hormone secretagogue ibutamoren, the peroxisome proliferator-activated receptor-δ agonist GW501516, and the Rev-ErbA agonist SR9009. Of the 44 tested products, no active compound was detected in 4 (9%) and substances not listed on the label were contained in 11 (25%). In only 18 of the 44 products (41%), the amount of active compound in the product matched that listed on the label. The amount of the compounds listed on the label differed substantially from that found by analysis in 26 of 44 products (59%). Conclusions and Relevance: In this limited investigation involving chemical analyses of 44 products marketed as selective androgen receptor modulators and sold via the internet, most products contained unapproved drugs and substances. Only 52% contained selective androgen receptor modulators and many were inaccurately labeled.
Importance: Recent reports have described the increasing use of nonsteroidal selective androgen receptor modulators, which have not been approved by the US Food and Drug Administration (FDA), to enhance appearance and performance. The composition and purity of such products is not known. Objective: To determine the chemical identity and the amounts of ingredients in dietary supplements and products marketed and sold through the internet as selective androgen receptor modulators and compare the analyzed contents with product labels. Design and Setting: Web-based searches were performed from February 18, 2016, to March 25, 2016, using the Google search engine on the Chrome and Internet Explorer web browsers to identify suppliers selling selective androgen receptor modulators. The products were purchased and the identities of the compounds and their amounts were determined from April to August 2016 using chain-of-custody and World Anti-Doping Association-approved analytical procedures. Analytical findings were compared against the label information. Exposures: Products marketed and sold as selective androgen receptor modulators. Main Outcomes and Measures: Chemical identities and the amount of ingredients in each product marketed and sold as selective androgen receptor modulators. Results: Among 44 products marketed and sold as selective androgen receptor modulators, only 23 (52%) contained 1 or more selective androgen receptor modulators (Ostarine, LGD-4033, or Andarine). An additional 17 products (39%) contained another unapproved drug, including the growth hormone secretagogue ibutamoren, the peroxisome proliferator-activated receptor-δ agonist GW501516, and the Rev-ErbA agonist SR9009. Of the 44 tested products, no active compound was detected in 4 (9%) and substances not listed on the label were contained in 11 (25%). In only 18 of the 44 products (41%), the amount of active compound in the product matched that listed on the label. The amount of the compounds listed on the label differed substantially from that found by analysis in 26 of 44 products (59%). Conclusions and Relevance: In this limited investigation involving chemical analyses of 44 products marketed as selective androgen receptor modulators and sold via the internet, most products contained unapproved drugs and substances. Only 52% contained selective androgen receptor modulators and many were inaccurately labeled.
Authors: Mario Thevis; Andreas Lagojda; Dirk Kuehne; Andreas Thomas; Josef Dib; Annelie Hansson; Mikael Hedeland; Ulf Bondesson; Tina Wigger; Uwe Karst; Wilhelm Schänzer Journal: Rapid Commun Mass Spectrom Date: 2015-06-15 Impact factor: 2.419
Authors: Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin Journal: Endocr Rev Date: 2013-12-17 Impact factor: 19.871
Authors: V Abbate; A T Kicman; M Evans-Brown; J McVeigh; D A Cowan; C Wilson; S J Coles; C J Walker Journal: Drug Test Anal Date: 2014-10-06 Impact factor: 3.345
Authors: Mary E Westerman; Cameron M Charchenko; Matthew J Ziegelmann; George C Bailey; Todd B Nippoldt; Landon Trost Journal: Mayo Clin Proc Date: 2016-01-05 Impact factor: 7.616
Authors: Laura A Solt; Yongjun Wang; Subhashis Banerjee; Travis Hughes; Douglas J Kojetin; Thomas Lundasen; Youseung Shin; Jin Liu; Michael D Cameron; Romain Noel; Seung-Hee Yoo; Joseph S Takahashi; Andrew A Butler; Theodore M Kamenecka; Thomas P Burris Journal: Nature Date: 2012-03-29 Impact factor: 49.962
Authors: Michael D Nyquist; Lisa S Ang; Alexandra Corella; Ilsa M Coleman; Michael P Meers; Anthony J Christiani; Cordell Pierce; Derek H Janssens; Hannah E Meade; Arnab Bose; Lauren Brady; Timothy Howard; Navonil De Sarkar; Sander B Frank; Ruth F Dumpit; James T Dalton; Eva Corey; Stephen R Plymate; Michael C Haffner; Elahe A Mostaghel; Peter S Nelson Journal: J Clin Invest Date: 2021-05-17 Impact factor: 14.808
Authors: Jason M Nagata; Kyle T Ganson; Mitchell L Cunningham; Deborah Mitchison; Jason M Lavender; Aaron J Blashill; Holly C Gooding; Stuart B Murray Journal: PLoS One Date: 2020-12-15 Impact factor: 3.240